Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
This study has been terminated.
(Lack of recruitment and the company's decision to de-prioritize 5584 development)
First Posted: November 25, 2013
Last Update Posted: January 27, 2017
Information provided by (Responsible Party):